A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants

Development of safe and efficient vaccines is still necessary to deal with the COVID-19 pandemic. Herein, we reported that yeast-expressed recombinant RBD proteins either from wild-type or Delta SARS-CoV-2 were able to elicit immune responses against SARS-CoV-2 and its variants. The wild-type RBD (w...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu, Zhao, Danhua, Wang, Yichang, Chen, Zhian, Yang, Li, Li, Wenjuan, Gong, Yanqiu, Gan, Chunmei, Tang, Jieshi, Zhang, Tizhong, Tang, Dan, Dong, Xiuju, Yang, Qingzhe, Valencia, C. Alexander, Dai, Lunzhi, Qi, Shiqian, Dong, Biao, Chow, Hoi Yee, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682237/
https://www.ncbi.nlm.nih.gov/pubmed/36439096
http://dx.doi.org/10.3389/fimmu.2022.1011484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682237/
https://www.ncbi.nlm.nih.gov/pubmed/36439096
http://dx.doi.org/10.3389/fimmu.2022.1011484

Ejemplares similares